CLDN5 and relapsing-remitting multiple sclerosis: Furthermore, our previous data demonstrated that sera obtained from patients with relapsing RRMS as well as SPMS disrupt the BBB via a decrease in the expression of claudin-5 proteins in BMECs [9].